RNA-seq of bone marrow samples from acute myeloid leukemia patients and healthy individuals

Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults, characterized by the malignant transformation and uncontrolled proliferation of abnormal myeloid hematopoietic progenitor cells in the bone marrow. This study aims to analyze the pathogenesis and prognosis of AML by performing RNA-seq on bone marrow samples from both AML patients and healthy individuals. We collected a total of 20 bone marrow samples, consisting of 10 samples from AML patients and 10 from healthy controls, all of which were stored in liquid nitrogen. The study received ethical approval (Ethical Approval Number: KY2024070), and all participants signed informed consent forms. This dataset includes the RNA-seq data from these samples. By analyzing the gene expression characteristics of myeloid progenitor cells, we attempt to construct a prognostic model to guide clinical treatment. These data not only aid in further exploring the molecular mechanisms of AML but also serve to identify new biomarkers and develop prognostic models, which are valuable for understanding the gene expression differences between AML and healthy bone marrow samples. The sharing of data from this study strictly adheres to ethical guidelines, with all sample collection and usage approved by the ethics committee and consented to by the participants.

Methods
A total of 20 bone marrow samples were collected for this study, consisting of 10 bone marrow samples from patients with acute myeloid leukemia (AML) (AML group), and 10 bone marrow samples from healthy individuals (control group). All AML patients were diagnosed by bone marrow smear morphology and cytogenetic testing, and individuals in the healthy control group underwent a thorough physical examination to exclude any history of blood disorders and tumors. The samples were stored in liquid nitrogen for further processing. All subjects signed an informed consent form, and the study was approved by the Ethics Committee of the Affiliated Hospital of Southwest Medical University (Ethics Approval No. KY2024070).

Total RNA was extracted from frozen bone marrow samples using TRIzol reagent (Thermo Fisher Scientific, USA) for RNA extraction according to the manufacturer's instructions. The quality of extracted RNA was assessed by Agilent 2100 Bioanalyzer to ensure that the RNA Integrity Index (RIN) was greater than 7.0.RNA concentration was quantified using Qubit 2.0 (Thermo Fisher Scientific) to ensure that sequencing requirements were met.RNA library construction was performed using the Illumina TruSeq RNA Library Prep Kit (Illumina, USA), and library quality control was performed by Qubit and Bioanalyzer. All samples were bipartite sequenced on the Illumina NovaSeq 6000 platform with a read length of 150 bp and a target sequencing depth of 50M reads per sample.